The choice of breast cancer therapy is based on a number of criteria, including tumor histology, hormone receptor expression, axillary lymph node status, HER2 status and presence of metastases, as well as patient characteristics, such as menopausal status, age and comorbidities (Waks and Winer, 2019). This evidence concerns the gene ERBB2 and neoplasm.